To match the growing demand for biopharmaceutical development and manufacturing, Catalent Biologics has invested extensively in its network to create a comprehensive end-to-end offering for its customers.
To match the growing demand for biopharmaceutical development and manufacturing, Catalent Biologics has invested extensively in its network to create a comprehensive end-to-end offering for customers that includes cell line development, analytical testing, clinical and commercial biomanufacturing, antibody-drug conjugate (ADC) development, fill-finish, and clinical supply services.
The acquisition and integration of Cook Pharmica, LLC’s Bloomington, Indiana facility into Catalent Biologics’ network has strengthened the company’s position as a leader in clinical and commercial-scale biomanufacturing and finished product supply. The acquisition adds expertise in fill/finish liquid and lyophilised vials, prefilled syringes, and cartridges, secondary packaging, including auto-injectors and safety devices, and 2,500 litres of biomanufacturing capacity.
In addition to the Bloomington site, Catalent Biologics’ network includes a state-of-the-art development and manufacturing facility in Madison, Wisconsin; SMARTag® ADC technology in Emeryville, California, prefilled syringe services in Brussels, Belgium; and a network of biologics analytical labs and clinical supply sites around the globe.
Investment and expansion has recently been undertaken at the Madison facility to accommodate two new, 2,000 litre single-use bioreactor systems, enabling late-phase clinical and commercial production of up to 4,000 litre batches. Analytical and process development laboratories at the site have also been expanded to meet greater capacity and capabilities.